These findings may be validated clinically in a phase II clinical trial where post-menopausal patients with AI-resistant, ER+, HER2-negative, PIK3CA-mutant breast cancer are randomized to treatment with another AI plus a PI3K inhibitor vs. fulvestrant plus a PI3K inhibitor (Figure 3). Here, PIK3CA is linked to breast carcinoma.